Arkiv: Webcasts

Briox – Q2 presentation 2023

Bolagets vd Johan Nordqvist och styrelseordförande Erik Hammarberg presenterar Q2 2023 och svarar på frågor från tittarna.

AlzeCure Pharma – Capital Market Day

Program:

10:00 Welcome address & agenda – Martin Jönsson, CEO, AlzeCure

10:02 AlzeCure Pharma: Overview, vision & update – Martin Jönsson, CEO, AlzeCure

10:10 Alzheimer’s disease, societal challenges & recent developments in the field – Professor Bengt Winblad, M.D., PhD, Karolinska Institute

10:25 Alzstatin: Background & evolution – Johan Sandin, PhD, CSO, AlzeCure

10:45 NeuroRestore: Background & data supporting disease modifying effects – Pontus Forsell, PhD, Head of Discovery & Research, AlzeCure

11:05 Panel discussion & QnA – Lead by Ludwig Sjöström, FinWire

11:25 Concluding remarks – Martin Jönsson, CEO, AlzeCure

Fluicell

Founded in 2012 as a spin-off from Chalmers University of Technology in Sweden, Fluicell is a public biotech company specializing in high resolution bioprinting and single-cell biology. The company is a world leader and pioneer in open-volume microfluidics for the life sciences, and holds a strong IP and patent position with five different patent families in the estate.

The product portfolio consists of the 3D single-cell bioprinting platforms Biopixlar and Biopixlar AER and a product series for single-cell biological and pharmacological research, consisting of BioPen, Biozone 6 and Dynaflow Resolve.